| 摘要 |
The present invention relates to differentially expressed kallikrein molecules and more particularly to novel expression products of the KLK5 and KLK7 genes, which are differentially expressed between normal and cancer cells and which serve as targets for diagnosis and therapeutic intervention of cancers, especially serous cancers such as ovarian cancer.
|
